My watch list  

Interferon beta-1b

Interferon beta-1b
Systematic (IUPAC) name
Human interferon beta
CAS number 145155-23-3
ATC code L03AB08
PubChem  ?
DrugBank BTD00078
Chemical data
Formula C908H1408N246O253S6 
Mol. mass 20011.0 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Interferon beta-1b (marketed as Betaseron) is a drug in the interferon family used to treat the relapsing-remitting form of multiple sclerosis. It is administered by sub-cutaneous injection and has been shown to slow the advance of the affliction as well as reduce the frequency of attacks. Betaseron is manufactured by Berlex Corporation.

It is believed that Interferon-Beta based drugs achieve their beneficial effect on MS progress via their anti-inflammatory properties. Studies have also determined that Interferon-Beta improves the integrity of the blood-brain barrier (BBB)—which generally breaks down in MS patients, allowing increasing amounts of undesirable substances to reach the brain. This strengthening of the BBB may be a contributing factor to Interferon-Beta's beneficial effects. These studies were carried out in vitro, so it does not necessarily mean it works the same in people.

Closely related is Interferon beta-1a, also indicated for multiple sclerosis, and with a very similar drug profile.

See also

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Interferon_beta-1b". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE